Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II

Journal of Bone and Mineral Research

Volumn 21, Issue 2, 2006, Pages 219-227

  Katagiri, Mika ^a   Ogasawara, Toru ^a   Hoshi, Kazuto ^a   Chikazu, Daichi ^a   Kimoto, Aishi ^b   Noguchi, Masahiro ^b   Sasamata, Masao ^b   Harada, Shun Ichi ^c   Akama, Hideto ^d   Tazaki, Hatsue ^e   Chung, Ung Il ^a   Takato, Tsuyoshi ^a   Nakamura, Kozo ^a   Kawaguchi, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PFIZER INC   (United States)

^e JAPAN TOBACCO INC   (Japan)

Author keywords

Arthritis; Bone resorption; Carbonic anhydrase; Cyclooxygenase; Osteoclast; Prostaglandin

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETAZOLAMIDE; CARBONATE DEHYDRATASE II; CARBOXY TERMINAL TELOPEPTIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; S 560; TILMACOXIB;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; BONE RADIOGRAPHY; CELL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE RESORPTION; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CELL DIFFERENTIATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED STRAINS; OSTEOARTHRITIS; OSTEOCLASTS; RATS; RATS, INBRED LEW;

EID: 33144462779     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.051025     Document Type: Article

References (53)

1. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T 1985 Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 28:25-31.
2. Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H 1999 Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatol 38:714-720.
3. Nakano K, Okada Y, Saito K, Tanaka Y 2004 Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 50:2450-2458.
4. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T, Iwamoto Y, Nagai Y, Hasegawa M, Sueishi K 2002 Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 168:450-457.
5. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG 1995 The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 313:36-46.
6. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
7. Fuller K, Chambers TJ 1989 Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts. J Bone Miner Res 4:209-215.
8. Kawaguchi H, Pilbeam CC, Gronowicz G, Abreu C, Fletcher BS, Herschman HR, Raisz LG, Hurley MM 1995 Transcriptional induction of prostaglandin G/H synthase-2 by basic fibloblast growth factor. J Clin Invest 96:923-930.
9. Kawaguchi H, Nemoto K, Raisz LG, Harrison JR, Voznesensky OS, Alander CB, Pilbeam CC 1994 Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures. J Bone Miner Res 11:358-366.
10. Kawaguchi H, Chikazu D, Nakamura K, Kumegawa M, Hakeda Y 2000 Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. J Bone Miner Res 15:466-473.
11. Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, Nakamura K, Kawaguchi H 2001 Regulation of osteoclast differentiation by fibroblast growth factor 2: Stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Miner Res 16:2074-2081.
12. Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, Pilbeam CC 2000 Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105:823-832.
13. Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG 1995 Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest 96:539-548.
14. Schuna AA, Megeff C 2000 New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm 57:225-234.
15. Nakamura YS, Hakeda Y, Takekura N, Kameda T, Hamaguchi I, Miyamoto T, Kakudo S, Nakano T, Kumegawa M, Suda T 1998 Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts. Stem Cells 18:229-238.
16. Chikazu D, Hakeda Y, Ogata N, Nemoto K, Itabashi A, Takato T, Kumegawa M, Nakamura K, Kawaguchi H 2000 Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J Biol Chem 275:31444-31450.
17. Katagiri M, Hakeda Y, Chikazu D, Ogasawara T, Takato T, Kumegawa M, Nakamura K, Kawaguchi H 2001 Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol Chem 276:7376-7382.
18. Bekker PJ, Gay CV 1990 Biochemical characterization of an electrogenic vacuolar proton pump in purified chicken osteoclast plasma membrane vesicles. J Bone Miner Res 6:569-579.
19. Rousselle AV, Heymann D 2002 Osteoclastic acidification pathways during bone resorption. Bone 30:533-540.
20. Teti A, Blair HC, Teitelbaum SL, Kahn AJ, Koziol C, Konsek J, Zambonin-Zallone A, Schlesinger PH 1989 Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J Clin Invest 83:227-233.
21. +-ATPase. J Clin Invest 93:2311-2318.
22. Sly WS, Hu PY 1995 Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 64:375-401.
23. Asotra S, Gupta AK, Sodek J, Aubin JE, Heershe JNM 1995 Carbonic anhydrase II mRNA expression in individual osteoclasts under "resorbing" and "nonresorbing" conditions. J Bone Miner Res 9:1115-1122.
24. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G 2004 Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-Selective celecoxib: New pharmacological opportunities due to related binding site recognition. J Med Chem 47:550-557.
25. Zimmermann M 1983 Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.
26. Matsushita M, Masaki M, Yagi Y, Tanaka T, Wakitani K 1997 Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats. Inflamm Res 46:461-466.
27. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275-286.
28. Wilbur KM, Anderson NG 1948 Electrometric and colorlimetric determination of carbonic anhydrase. J Biol Chem 176:147-154.
29. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N 2001 The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 232:235-247.
30. Olsen NJ, Stein CM 2004 New drugs for rheumatoid arthritis. N Engl J Med 350:2167-2179.
31. Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, Gasser J, Bergmeister H, Kollias G, Smolen JS, Schett G 2004 Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 50:2327-2337.
32. Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E 2004 Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50:2338-2346.
33. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Quellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I 1999 Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560.
34. Masaki M, Matsushita M, Wakitani K1998 Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats. Inflamm Res 47:187-192.
35. Nolan JC, Gathright CE, Radvany CH, Barrett IU, Sancilio LF 1991 Carbonic anhydrase inhibitors are antiarthritic in the rat. Pharmacol Res 24:377-383.
36. Mandal U, Ganesan M, Jayakumar M, Pal TK, Chattaraj TK, Ray K, Banerjee SN 2003 High performance liquid chromatographic determination of Cox-2 inhibitor rofecoxib in human plasma. J Indian Med Assoc 101:486-488.
37. Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP, Baillie TA 2002 The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab Dispos 30:684-693.
38. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Study Group VIGOR 2000 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528.
39. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS 2000 Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255.
40. FitzGerald GA, Patrone C 2001 The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442.
41. Supuran CT, Casini A, Mastrolorenzo A, Scozzafava A 2004 Cox-2 selective inhibitors, carbonic anhydrase inhibition and anticancer propaties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med Chem 4:625-632.
42. Juni P, Dieppe P 2004 Older people should NOT be prescribed "coxibs" in place of conventional NSAIDs. Age Ageing 33:100-104.
43. Dieppe PA, Ebrahim S, Martin RM, Juni P 2004 Lessons from the withdrawal of rofecoxib. BMJ 329:867-868.
44. Inoue K, Motonaga A, Suzuka H, Yoshifusa H, Fujisawa H, Nishimura T, Inoue Y, Ueda F, Shibata Y, Kimura K 1993 Effect of etodolac on type-II collagen-induced arthritis in mice. Agents Actions 39:187-194.
45. Weichman BM, Chau TT, Rona G 1987 Histopathologic evaluation of the effects of etodolac in established adjuvant arthritis in rats: Evidence for reversal of joint damage. Arthritis Rheum 30:466-470.
46. Engelhardt G, Homma D, Schnitzler C 1995 Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 44:548-555.
47. Igarashi K, Woo JT, Stern PH 2002 Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochem Pharmacol 63:523-532.
48. Venta PJ, Montgomery JC, Hewett-Emmett D, Wiebauer K, Tashian RE 1985 Structure and exon to protein domain relationships of the mouse carbonic anhydrase II gene. J Biol Chem 260:12130-12135.
49. Murakami H, Marelich GP, Grubb JH, Kyle JW, Sly WS 1987 Cloning, expression, and sequence homologies of cDNA for human carbonic anhydrase II. Genomics 1:159-166.
50. Song JH, Sirois J, Houde A, Murphy BD 1998 Cloning, developmental expression, and immunohistochemistry of cyclooxygenase 2 in the endometrium during embryo implantation and gestation in the mink. Endocrinology 139:3629-3636.
51. Gerstenfeld LC, Einhorn TA 2004 COX inhibitors and their effects on bone healing. Expert Opin Drug Saf 3:131-136.
52. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL 2002 COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 20:1164-1169.
53. Goodman SB, Ma T, Mitsunaga L, Miyanishi K, Genovese MC, Smith RL 2005 Temporal effects of a COX-2-selective NSAID on bone ingrowth. J Biomed Mater Res A 72:279-287.